RA CAPITAL MANAGEMENT, L.P. Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001346824

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q4 2025 · 71 positions · Total reported value $9.76B · Top-10 concentration 65.6% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 38.4% · 15 new · 12 cut · 11 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -13.6% · vs SPY -15.8% · Prev Value $11.51B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -1.6% · vs SPY -3.7% · Latest Value $9.72B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q4 2025 13F filing, RA CAPITAL MANAGEMENT, L.P. disclosed 71 equity positions with a combined reported value of $9.76B. The filing implies a focused portfolio: its ten largest positions account for 65.6% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q4 2025 were ASND ($2.19B), CDTX ($743.41M), RYTM ($713.62M). By sector, the heaviest allocations are Health Care 82.9%, Technology 0.1%.

Versus the prior quarter, RA CAPITAL MANAGEMENT, L.P. opened 15 new positions, trimmed 12 and fully exited 11, a turnover rate of 38.4% of positions. The portfolio's overlap with the prior quarter was 57% of names.

The largest new positions opened in Q4 2025 were BCRX ($123.45M), PRAX ($110.17M), OLMA ($65.00M).

Of the 11 positions fully exited versus the prior quarter, the largest were ETNB ($292.38M), SRRK ($43.45M), GPCR ($42.49M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q4 2025)

  • BCRX BIOCRYST PHARMACEUTICALS INC · $123.45M
  • PRAX PRAXIS PRECISION MEDICINES I · $110.17M
  • OLMA OLEMA PHARMACEUTICALS INC · $65.00M
  • EVMN EVOMMUNE INC · $59.21M
  • SYRE SPYRE THERAPEUTICS INC · $53.12M
  • LXEO LEXEO THERAPEUTICS INC · $49.65M
  • CAPR CAPRICOR THERAPEUTICS INC · $43.52M
  • GRAL GRAIL INC · $36.66M

Fully Exited (vs previous quarter)

  • ETNB 89BIO INC · prev qtr: $292.38M
  • SRRK SCHOLAR ROCK HLDG CORP · prev qtr: $43.45M
  • GPCR STRUCTURE THERAPEUTICS INC · prev qtr: $42.49M
  • MTSR METSERA INC · prev qtr: $35.35M
  • TVTX TRAVERE THERAPEUTICS INC · prev qtr: $27.48M
  • LRMR LARIMAR THERAPEUTICS INC · prev qtr: $19.53M
  • TNGX TANGO THERAPEUTICS INC · prev qtr: $16.80M
  • PRME PRIME MEDICINE INC · prev qtr: $16.62M

Insider Transactions (Form 4)

Latest RA CAPITAL MANAGEMENT, L.P. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-11-02 Buy Bambusa Therapeutics, Inc. 164,891 $16.00 SEC filing
2026-11-02 Buy Bambusa Therapeutics, Inc. 2,335,109 $16.00 SEC filing
2026-11-02 Conversion Bambusa Therapeutics, Inc. 1,331,080 — SEC filing
2026-11-02 Conversion Bambusa Therapeutics, Inc. 3,144,858 — SEC filing
2026-10-30 Buy Bambusa Therapeutics, Inc. 263,911 $14.92 SEC filing
2026-10-30 Buy Bambusa Therapeutics, Inc. 189,909 $14.23 SEC filing
2026-10-29 Sell LENZ Therapeutics, Inc. 107,170 $3.36 SEC filing
2026-10-29 Sell LENZ Therapeutics, Inc. 451,998 $3.36 SEC filing

All insider transactions →

Fund Profile

RA Capital Management is a Boston-based investment firm founded by Peter Kiernan, specializing in healthcare-focused investments with a long-term, value-oriented approach.

Investment Approach

Focuses on healthcare sector investments

Long-term, value-oriented strategy

Deep fundamental research and analysis

Asset Classes & Strategy

Primarily invests in public equities

Also manages private investments in healthcare companies

Concentrated portfolio approach with significant positions in healthcare companies

Key Personnel

Peter Kiernan: Founder and portfolio manager

Team of experienced investment professionals with healthcare expertise

Notable Facts

Founded in 2002

Manages approximately $16.4 billion in assets

Files SEC Form 13F for US equity positions

This profile is based on publicly available information and should not be considered as official disclosure from the firm.

Sector Allocation

Health Care 82.9%
Technology 0.1%
Materials 0.1%
Other 16.9%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 10.28M $2.19B 22.46%
22.46%
Hold
2 3.37M $743.41M 7.62%
7.62%
Hold
3 6.67M $713.62M 7.31%
7.31%
Add
4 8.64M $623.28M 6.38%
6.38%
Hold
5 10.72M $494.83M 5.07%
5.07%
Reduce
6 9.91M $407.49M 4.17%
4.17%
Reduce
7 9.55M $335.02M 3.43%
3.43%
Reduce
8 12.20M $320.70M 3.29%
3.29%
Hold
9 18.20M $309.45M 3.17%
Form 4 · 1 →
3.17%
Hold
10 7.32M $265.78M 2.72%
2.72%
Hold
11 10.43M $258.78M 2.65%
2.65%
Hold
12 7.00M $195.04M 2.00%
2.00%
Hold
13 1.88M $189.11M 1.94%
1.94%
Add
14 1.98M $156.92M 1.61%
1.61%
Add
15 11.19M $154.42M 1.58%
1.58%
Hold
16 20.06M $130.62M 1.34%
1.34%
Hold
17 23.56M $129.56M 1.33%
1.33%
Hold
18 10.86M $126.53M 1.30%
1.30%
Hold
19 15.83M $123.45M 1.26%
1.26%
New
20 6.96M $117.07M 1.20%
1.20%
Hold
21 373.79K $110.17M 1.13%
1.13%
New
22 7.68M $97.49M 1.00%
1.00%
Hold
23 63.77M $84.18M 0.86%
0.86%
Add
24 1.27M $82.62M 0.85%
0.85%
Reduce
25 11.29M $77.71M 0.80%
Form 4 · 4 →
0.80%
Reduce
26 5.40M $70.70M 0.72%
Form 4 · 1 →
0.72%
Add
27 432.48K $69.18M 0.71%
0.71%
Reduce
28 6.05M $68.47M 0.70%
0.70%
Reduce
29 4.18M $66.86M 0.69%
Form 4 · 3 →
0.69%
Hold
30 1.61M $66.42M 0.68%
0.68%
Reduce
31 2.60M $65.00M 0.67%
0.67%
New
32 3.46M $59.21M 0.61%
0.61%
New
33 3.67M $56.64M 0.58%
0.58%
Add
34 1.62M $53.12M 0.54%
0.54%
New
35 5.00M $49.65M 0.51%
0.51%
New
36 2.21M $49.16M 0.50%
0.50%
Add
37 667.21K $43.57M 0.45%
0.45%
Add
38 1.51M $43.52M 0.45%
0.45%
New
39 5.65M $42.40M 0.43%
0.43%
Add
40 17.12M $42.28M 0.43%
0.43%
Hold
41 9.85M $42.27M 0.43%
0.43%
Hold
42 428.27K $36.66M 0.38%
0.38%
New
43 1.02M $34.70M 0.36%
0.36%
Hold
44 5.81M $32.78M 0.34%
0.34%
Hold
45 14.93M $31.51M 0.32%
0.32%
Hold
46 1.85M $24.92M 0.26%
0.26%
New
47 2.18M $24.91M 0.26%
0.26%
Add
48 9.18M $21.66M 0.22%
0.22%
New
49 8.34M $20.10M 0.21%
0.21%
Hold
50 10.81M $19.99M 0.20%
0.20%
Hold

FAQ

What did RA CAPITAL MANAGEMENT, L.P. buy in 2025-Q4?

In its 2025-Q4 13F filing, RA CAPITAL MANAGEMENT, L.P. reported 71 equity positions worth $9.76B in aggregate; its largest disclosed positions were ASND ($2.19B), CDTX ($743.41M), RYTM ($713.62M).

How large is RA CAPITAL MANAGEMENT, L.P.'s portfolio?

RA CAPITAL MANAGEMENT, L.P. reported $9.76B of long equity holdings across 71 positions as of 2025-Q4. Top-10 holdings account for 65.6% of reported value.

What is RA CAPITAL MANAGEMENT, L.P.'s investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/ra-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →